regulatory affairs

Topic: regulatory affairs Paper details:  review the comments : In section 2.1.1  update the highlighted section to reflect what is on the table in" rel="nofollow">in 2.a. In table 2.b please do an analysis for Stalevo, Neupro, Azilect. Then please look at the 2.1.3 section table 2.c and recheck the in" rel="nofollow">information for advisory groups.Then Please reword what is in" rel="nofollow">in the highlighted section of 2.1.4.1, 2.1.4.2,2.1.4.3,2.1.4.4,2.1.4.5. Then look at the drug list in" rel="nofollow">in table 2.a and see if the writer can fin" rel="nofollow">ind any failed marketin" rel="nofollow">ing applications and do a write up in" rel="nofollow">in sect 2.2 which is highlighted. Then recheck table 2.f. Look at the drug list in" rel="nofollow">in table 2 a and provideÕÉ≠†Њ† a write up on in" rel="nofollow">indication­specific contradictions, warnin" rel="nofollow">ing and precautions section 3.2.2 which is highlighted .Then provide a write up for parkin" rel="nofollow">insons 3.2.3 just like the highlighted example that was a excerpt from the rheumatoid arthritis in" rel="nofollow">indication module example. Lastly please update the reference section 4.0 to look like the example . Please let me know if you have any questions